Harnessing the PD-L1 interface peptide for positron emission tomography imaging of the PD-1 immune checkpoint.

Autor:	Hu K; Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology Chiba, 263-8555 Japan zhang.ming-rong@qst.go.jp., Xie L; Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology Chiba, 263-8555 Japan zhang.ming-rong@qst.go.jp., Hanyu M; Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology Chiba, 263-8555 Japan zhang.ming-rong@qst.go.jp., Zhang Y; Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology Chiba, 263-8555 Japan zhang.ming-rong@qst.go.jp., Li L; School of Chemistry and Chemical Engineering, Beijing Institute of Technology Beijing 100081 P. R. China wangwz@bit.edu.cn., Ma X; Department of Vascular Surgery, General Hospital of People's Liberation Army Beijing 100853 P. R. China., Nagatsu K; Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology Chiba, 263-8555 Japan zhang.ming-rong@qst.go.jp., Suzuki H; Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology Chiba, 263-8555 Japan zhang.ming-rong@qst.go.jp., Wang W; School of Chemistry and Chemical Engineering, Beijing Institute of Technology Beijing 100081 P. R. China wangwz@bit.edu.cn., Zhang MR; Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology Chiba, 263-8555 Japan zhang.ming-rong@qst.go.jp.
Jazyk:	angličtina
Zdroj:	RSC chemical biology [RSC Chem Biol] 2020 Aug 27; Vol. 1 (4), pp. 214-224. Date of Electronic Publication: 2020 Aug 27 (Print Publication: 2020).
DOI:	10.1039/d0cb00070a
Abstrakt:	Interface peptides that mediate protein-protein interactions (PPI) are a class of important lead compounds for designing PPI inhibitors. However, their potential as precursors for radiotracers has never been exploited. Here we report that the interface peptides from programmed death-ligand 1 (PD-L1) can be used in positron emission tomography (PET) imaging of programmed cell death 1 (PD-1) with high accuracy and sensitivity. Moreover, the performance differentiation between murine PD-L1 derived interface peptide (mPep-1) and human PD-L1 derived interface peptide (hPep-1) as PET tracers for PD-1 unveiled an unprecedented role of a non-critical residue in target binding, highlighting the significance of PET imaging as a companion diagnostic in drug development. Collectively, this study not only provided a first-of-its-kind peptide-based PET tracer for PD-1 but also conveyed a unique paradigm for developing imaging agents for highly challenging protein targets, which could be used to identify other protein biomarkers involved in the PPI networks. Competing Interests: There are no conflicts to declare. (This journal is © The Royal Society of Chemistry.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu